We are focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions. Our team of experienced and accomplished kinome experts use the proprietary KINect® technology platform to generate clinical candidates for difficult to drug kinases with novel approaches. The ability to systemically and efficiently attach human kinases with adenosine triphosphate (ATP) site cysteines (the human cysteinome) differentiates Aclaris from competitors.

Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization, as an indirect, wholly-owned subsidiary. Confluence serves as a research partner for pharma and biotech companies across therapeutic areas and gene families. Confluence’s expertise includes cell and molecular biology, biochemistry, enzymology, biomarker development, immunology and inflammation, in vivo efficacy models, bioanalytical, computational and medicinal chemistry. To learn more, visit www.confluencediscovery.com.